Intercept’s Ocaliva: ‘Dangling’ PBC Indication At Risk As Near-Term NASH Approval Looks Unlikely

 
• By Sue Sutter
Dangling shoes
Ocaliva appears to fit FDA's definition of a 'dangling' accelerated approval - when prespecified postmarketing trials do not confirm benefit but marketing continues. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards